Celcuity (CELC) News Today

Celcuity, Inc. (NASDAQ: CELC) — The stock is trading lower today amid mixed catalysts: a major positive clinical readout that has already driven a large run-up in the shares, offset by sizable insider selling and near‑term analyst model cuts that may prompt profit‑taking and re‑rating. Upcoming first‑quarter results and a webcast (May 14) add short‑term event risk and volatility.

• Positive Sentiment: Phase III clinical win — gedatolisib showed a survival benefit in PIK3CA+ metastatic breast cancer, a potential transformational commercial and regulatory catalyst if confirmed; this result underpins much of the recent rally and long‑term upside expectations. Gedatolisib Improves Survival
• Positive Sentiment: Analyst support — Guggenheim reiterated a Buy on CELC, reinforcing institutional confidence and providing buyer support after the clinical news. Guggenheim Keeps Their Buy Rating on Celcuity (CELC)
• Neutral Sentiment: Upcoming earnings/webcast — Celcuity will release Q1 2026 results after the close on May 14 with a management call the same day; results and commentary could magnify intraday moves and set the near‑term direction. Q1 2026 Results & Webcast
• Neutral Sentiment: HC Wainwright model mix — the firm trimmed near‑term quarterly EPS forecasts but materially raised medium/long‑range FY2027–FY2030 projections. That raises long‑term upside expectations while emphasizing negative near‑term cash/burn dynamics — a mixed signal for traders versus long‑term investors.
• Neutral Sentiment: Valuation discussion — commentary questioning whether CELC is overbought after a large one‑year surge can cool momentum as some investors lock gains and reassess risk/reward. Is It Too Late To Consider Celcuity?
• Negative Sentiment: Insider sales under 10b5‑1 plans — directors Richard Buller and David Dalvey sold large blocks (9,000 and 25,000 shares) at ~ $140.5 on May 4; while pre‑arranged plans limit signaling of private information, these sales increase supply and can contribute to short‑term downward pressure. Buller Form 4 Dalvey Form 4

Investor takeaway: Positive clinical data and refreshed analyst upside are supporting the stock’s long‑term thesis, but recent insider sales, shorter‑term analyst cuts and valuation concerns are prompting profit‑taking and increased volatility ahead of the May 14 quarterly release. Short‑term traders should watch the earnings call and insider filings; long‑term investors should weigh the Phase III result against execution, regulatory pathway and commercial assumptions.